[go: up one dir, main page]

ES2041796T3 - Un procedimiento para preparar una vacuna. - Google Patents

Un procedimiento para preparar una vacuna.

Info

Publication number
ES2041796T3
ES2041796T3 ES198888305166T ES88305166T ES2041796T3 ES 2041796 T3 ES2041796 T3 ES 2041796T3 ES 198888305166 T ES198888305166 T ES 198888305166T ES 88305166 T ES88305166 T ES 88305166T ES 2041796 T3 ES2041796 T3 ES 2041796T3
Authority
ES
Spain
Prior art keywords
vaccine
preparing
procedure
mumps
saccharose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888305166T
Other languages
English (en)
Inventor
Satoshi Makino
Keiko Sasaki
Masaharu Nakagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kitasato Institute
Original Assignee
Kitasato Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kitasato Institute filed Critical Kitasato Institute
Application granted granted Critical
Publication of ES2041796T3 publication Critical patent/ES2041796T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/20—Rubella virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA VACUNA QUE COMPRENDE AL MENOS UN VIRUS PLANO ATENUADO VIVO SELECCIONADO DE RUBELLA, Y COMO AGENTE ESTABILIZADOR, 2,5 A 5W/V% DE LACTOSA, 2,5 A 5 W/% DE SACAROSA, 1,8 A 2 W/V% O D-SOEBITOL, 0,1 W/V% GLUTAMATO SODICO Y 2 A 3 W/V % DE HIDROLIZADO DE GELATINA CON UN PESO MOLECULAR DE APROXIMADAMENTE 35.000.
ES198888305166T 1987-06-08 1988-06-07 Un procedimiento para preparar una vacuna. Expired - Lifetime ES2041796T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62142465A JPS63307827A (ja) 1987-06-08 1987-06-08 安定化された生ウイルスワクチンおよびその製造法

Publications (1)

Publication Number Publication Date
ES2041796T3 true ES2041796T3 (es) 1993-12-01

Family

ID=15315947

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888305166T Expired - Lifetime ES2041796T3 (es) 1987-06-08 1988-06-07 Un procedimiento para preparar una vacuna.

Country Status (8)

Country Link
US (1) US4985244A (es)
EP (1) EP0295043B1 (es)
JP (1) JPS63307827A (es)
KR (1) KR910009346B1 (es)
AT (1) ATE89742T1 (es)
BE (1) BE1001533A3 (es)
DE (1) DE3881281T2 (es)
ES (1) ES2041796T3 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3045581B2 (ja) * 1991-10-14 2000-05-29 社団法人北里研究所 麻疹ワクチンウイルス株同定方法
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
EP0736089A4 (en) * 1993-12-21 1999-08-11 Merck & Co Inc THERMOSTABLE VARICELLA ZOSTER VIRUS
WO1998028000A1 (en) * 1996-12-20 1998-07-02 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
GB9808922D0 (en) 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6586411B1 (en) * 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
JP2003513988A (ja) 1999-11-12 2003-04-15 ファイブローゲン、インコーポレーテッド ワクチンに含まれる組換えゼラチン
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
RU2158134C1 (ru) * 2000-03-10 2000-10-27 Унитарное Государственное "Московское Предприятие По Производству Бактерийных Препаратов" Способ получения ассоциированной паротитно-коревой вакцины
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
ES2545357T3 (es) 2010-09-02 2015-09-10 Mayo Foundation For Medical Education And Research Virus de la estomatitis vesicular
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
CN103599530B (zh) * 2013-10-30 2015-04-22 天津津斯特疫苗有限责任公司 一种用无血清培养基制备风疹减毒活疫苗的方法
SG11201610921PA (en) * 2014-07-18 2017-02-27 Msd Wellcome Trust Hilleman Lab Pvt Ltd A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
EP3234114B9 (en) * 2014-12-18 2023-06-14 Amgen Inc. Stable frozen herpes simplex virus formulation
JP7048482B2 (ja) 2015-08-03 2022-04-05 アメリカ合衆国 Ｂｒａｃｈｙｕｒｙ欠失変異体、Ｂｒａｃｈｙｕｒｙ欠失変異体をコードする非酵母ベクター、及びそれらの使用
US12150988B2 (en) * 2018-09-06 2024-11-26 Bavarian Nordic A/S Storage improved poxvirus compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2424031A1 (fr) * 1978-04-24 1979-11-23 Merck & Co Inc Stabilisateur de vaccin
PT71926B (en) * 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
DE3601922A1 (de) * 1986-01-23 1987-07-30 Behringwerke Ag Stabilisiertes virus-antigen, verfahren zu seiner herstellung und seine verwendung

Also Published As

Publication number Publication date
KR910009346B1 (ko) 1991-11-12
EP0295043B1 (en) 1993-05-26
DE3881281T2 (de) 1993-09-09
EP0295043A3 (en) 1989-07-26
JPS63307827A (ja) 1988-12-15
EP0295043A2 (en) 1988-12-14
US4985244A (en) 1991-01-15
BE1001533A3 (fr) 1989-11-21
DE3881281D1 (de) 1993-07-01
ATE89742T1 (de) 1993-06-15
KR890000107A (ko) 1989-03-11

Similar Documents

Publication Publication Date Title
ES2041796T3 (es) Un procedimiento para preparar una vacuna.
NO20073151L (no) Fremgangsmater og sammensetninger for a behandle hepatitt C virus
DK0745387T3 (da) Adjuvanser til virale vacciner
ATE272394T1 (de) Zubereitung mit verzögerter freisetzung
KR890004725A (ko) 신규 방법
DK0588578T3 (da) Immunogener
ATE196773T1 (de) Infektiösen bronchitis virus 4/91 enthaltender geflügel-impfstoff
NO176549C (no) Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk
HU9601462D0 (en) Adjuvants for viral vaccines
FI923347A0 (fi) Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
DE58900183D1 (de) Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
PT789590E (pt) Imunopotenciacao induzida por quitosano
ES2113348T3 (es) Composiciones de vacunas estabilizadas.
HUT65367A (en) Method for the preparation of chicken anaemia agent vaccine
DK1666057T3 (da) Fremgangsmåde til fremstilling af en acellulær vaccine indeholdende Bordetella pertussis antigener
LU91458I2 (fr) "Virus atténué des oreillons,souche RIT4385 (JL-1); virus atténué de la rougeole ; virus atténué de la rubéole ; et virus atténué de la varicelle."
ATE193287T1 (de) Herstellung von derivaten von a-acetyl neuraminicsäuren
DK0833903T3 (da) Multivalent vaccine mod bovint coronavirus og fremgangsmåde til behandling af infektioner forårsaget af bovint coronavirus
NO883520D0 (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
DE3884663D1 (de) Gefriergetrockneter, stabiler, lebendiger Herpesvirus-Impfstoff.
NZ228232A (en) Live combined vaccine comprising at least one live infectious bronchitis virus and at least one other virus infectious to poultry
IT1223171B (it) Procedimento per la preparazione di un ceppo mutante migliorato di bordetella bronchiseptica utile per un vaccino attenuato vivo per la protezione da infezioni di b. bronchiseptica e vaccino ar vivo attenuato cosi' ottenuto
ES8404188A1 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
ES2055610T3 (es) Vacuna contra hrsv.
DK0547446T3 (da) Vacciner på grundlag af ændrede bovine herpesvira type 1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 295043

Country of ref document: ES